| Trial ID: | L0520 |
| Source ID: | IRCT2017103030489N2
|
| Associated Drug: |
Polyunsaturated Fatty Acids
|
| Title: |
The effect of omega 3 polyunsaturated fatty acid supplementation on inflammatory markers and insulin resistanse factors in patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Condition 1: type 2 diabetes. Condition 2: Nonalcoholic fatty liver disease (NAFLD). <br>Non-insulin-dependent diabetes mellitus <br>Fatty (change of) liver, not elsewhere classified (NAFLD);Non-insulin-dependent diabetes mellitus;Fatty (change of) liver,
|
| Interventions: |
Intervention 1: omega-3, 1 gr soft gel, twice a day for 12 weeks. Intervention 2: placebo capsule containing Paraffin food, 1 gr soft gel, twice a day for 12 weeks.;Placebo;Placebo;omega-3, 1 gr soft gel, twice a day for 12 weeks;placebo capsule containin
|
| Outcome Measures: |
Fasting Insulin serum. Timepoint: baseline and after 12 weeks. Method of measurement: ELISA.;TNF-a. Timepoint: baseline and after 12 weeks. Method of measurement: ELISA.;IL-6. Timepoint: baseline and after 12 weeks. Method of measurement: ELISA.;Hs-CRP. Timepoint: baseline and after 12 weeks. Method of measurement: By Laboratory Kit.;HOMA-IR. Timepoint: baseline and after 12 weeks. Method of measurement: Blood Sampling and putting glucose and insulin levels in formula.;HOMA-??. Timepoint: baseline and after 12 weeks. Method of measurement: Blood Sampling and putting glucose and insulin levels in formula.;QUICKI. Timepoint: baseline and after 12 weeks. Method of measurement: formula calculation.;Beta cell function. Timepoint: baseline and after 12 weeks. Method of measurement: HOMA2 calculator software.nan
|
| Sponsor/Collaborators: |
Yazd Shahid Sadoughi University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 years60 years
|
| Phases: |
Phase 2/Phase 3
|
| Enrollment: |
48
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.
|
| Start Date: |
16/11/2017
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/24211
|
